Kilani Group and Sanofi Announce Strategic Partnership to Ensure Continuity and Development of Pharmaceutical Activities in Tunisia
Kilani Group and Sanofi announce the conclusion of a strategic partnership aimed at ensuring the continuity and development of Sanofi’s activities in Tunisia through the evolution of its operating model.
This new organization will sustainably secure Tunisian patients’ access to Sanofi’s therapeutic solutions, while strengthening the local anchoring of industrial and commercial activities and supporting the introduction of therapeutic innovations aligned with national health priorities.
Under this agreement, Sanofi’s activities in Tunisia will now be carried out by two entities of the Kilani Group:
- Teriak, which will be responsible for the local manufacturing of a portfolio of Sanofi medicines. Teriak operates modern manufacturing facilities and produces a wide range of pharmaceutical dosage forms. The company manufactures and distributes its own portfolio of generic medicines and produces, under license, medicines for several leading international pharmaceutical laboratories.
- Medicis, which will be responsible for medical and scientific information, interactions with health authorities, as well as the promotion of Sanofi’s therapeutic solutions within the Tunisian medical community.
This framework ensures full continuity of operations, a secure supply chain, and strengthened proximity to healthcare professionals.
A Partnership Serving the Tunisian Healthcare System
This evolution is part of a shared vision: maintaining the availability of essential medicines, ensuring a high level of quality, and actively contributing to the strengthening of the Tunisian healthcare system.
“We welcome the trust placed in Kilani Group by Sanofi to support this new strategic phase in Tunisia. Thanks to our industrial, logistical, and scientific capabilities, as well as our in-depth knowledge of the Tunisian market, we are fully committed to ensuring continuous access to treatments for patients. This partnership reflects our long-term commitment to public health in Tunisia,” said Sara Masmoudi, CEO of Kilani Group.
Sanofi stated:
“We express our deepest gratitude to the dedicated employees of Sanofi Tunisia who have served Tunisian patients throughout decades of shared history. We are opening a new chapter by partnering with a leading local player such as the Kilani Group, reflecting our commitment to sustainably ensuring access to our therapeutic solutions in Tunisia and to strengthening our engagement alongside health authorities and healthcare professionals,” said Rami Mroueh, General Manager Pharma Morocco-Tunisia-Libya at Sanofi.
About Kilani Group
Kilani Group is a leading player in the pharmaceutical and healthcare sector in Tunisia. Active across the entire value chain – local manufacturing, importation, distribution, and medical promotion – the Group contributes to the development of the healthcare sector and to strengthening Tunisia’s health sovereignty.
With 2,900 employees, Kilani Group relies on modern infrastructure, recognized expertise, and long-standing partnerships with leading international laboratories. Through its industrial and commercial subsidiaries, including Teriak and Medicis, the Group works every day to improve Tunisian patients’ access to high-quality medicines.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY